Clinical characteristics and prognosis of 16 relapsed/refractory B-cell malignancy patients with CAR T-cell-related hyperferritinaemia.

Zhou, Lanlan; Yu, Nanzhou; Li, Tongjuan; Ji, Hongyan; Jiang, Lijun; Wang, Di; Xu, Bin; Zhou, Xiaoxi

Zhou, Lanlan; Yu, Nanzhou; Li, Tongjuan; Ji, Hongyan; Jiang, Lijun; Wang, Di; Xu, Bin; Zhou, Xiaoxi.

Afiliación

Zhou L; Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Yu N; Department of Hematology, Tongji Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China.
Li T; Department of Hematology, Tongji Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ji H; Department of Hematology, Tongji Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jiang L; Department of Hematology, Tongji Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wang D; Department of Hematology, Tongji Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xu B; Department of Hematology, Tongji Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhou X; Department of Hematology, Tongji Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China.

Front Oncol ; 12: 912689, 2022.

Article en En | MEDLINE | ID: mdl-36313658

Palabras clave

B-cell malignancies; CAR T-cell therapy; clinical characteristics; hyperferritinaemia; prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google